Abstract We performed allogeneic hematopoietic stem cell transplantation in a patient with GATA2 deficiency and an Epstein-Barr virus (EBV)-related spindle cell tumor involving the liver and possibly bone. He received a matched-related donor transplant with donor peripheral blood stem cells following a myeloablative conditioning regimen. He achieved rapid and high levels of donor engraftment and had complete reversal of the clinical and immunologic phenotype of MonoMAC/GATA2 deficiency and eradication of the EBV tumors after 3 years of follow-up. Thus, allogeneic hematopoietic stem cell transplant results in reconstitution of immunologic function and cure of EBV-associated malignancy in MonoMAC/GATA2 deficiency.
Introduction
The indications for hematopoietic cell transplantation (HCT) for congenital immunodeficiencies continue to expand as new disease identification is enabled by whole exome sequencing [1] . As would be expected given the underlying indication for transplantation, this also expands the infectious complications present prior to transplantation. The outcomes of transplantation in the face of active infectious disease are an important field of study.
Haploinsufficiency of GATA2, a transcription factor necessary for hematopoietic stem cell maintenance and development, results in multiple manifestations including MonoMAC syndrome (monocytopenia with Mycobacterium avium complex [MAC] or non-tuberculous mycobacteria [NTM] infections), DCML (dendritic cell, monocyte, and NK lymphocyte deficiency), familial myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML), and Emberger syndrome (lymphedema and myelodysplatic syndrome). The cytopenias (monocytes, B and NK lymphocytes, and dendritic cells) also result in fungal, bacterial, and viral infections, the latter including those due to human papillomavirus and Epstein-Barr virus [2, 3] .
EBV viremia and smooth muscle tumors have been identified in a substantial number of GATA2-deficient patients [4] . In the original MonoMAC report, over 10% of patients developed persistent EBV infections or complications, including a posterior orbital leiomyosarcoma, which was excised prior to transplant. However, there was multifocal involvement at autopsy following complications from a matched-related donor HCT for chronic myelomonocytic leukemia (CMML) [3] .
Establishing therapies for EBV-related disease has presented an extraordinary challenge. The antagonism of viral replication by current drugs has not proven rewarding. Since the expression pattern of EBV proteins has been defined, these molecules have been studied as potential targets for immunotherapy [5, 6] . Unfortunately, the expression patterns of EBV genes in non-B cell malignancies and their relation to oncogenesis is not defined, nor is the presumption of a defect in EBV-specific immunity established. This leaves the question open as to the role of hematopoietic cell transplantation (HCT) in T cell, NK-cell, and mesenchymal EBV-associated tumors, which relies on graft-versus-tumor effect for its efficacy. These questions are relevant in the evolution of EBV-related disease in patients with GATA2 deficiency.
HCT has been reported by our group for the treatment of GATA2 deficiency and severe infections (predominantly disseminated NTM) [7] . We describe a young man with EBVassociated smooth muscle malignancy in the setting of GATA2 deficiency, and the correction of GATA2 deficiency and elimination of the EBV tumors with HCT.
Patients and Methods

Patients
The patient underwent screening/evaluation under a protocol to study the natural history, genetics, phenotype, and treatment of mycobacterial infections and allogeneic hematopoietic stem cell transplantation for patients with mutations in GATA2 or the MonoMAC syndrome. The studies were approved by the institutional review boards of the National Institute of Allergy and Infectious Diseases and the National Cancer Institute, respectively, and were independently monitored for safety and data accuracy. Informed consent was obtained for all patients and donors in accordance with the Declaration of Helsinki (ClinicalTrials.gov number, NCT00923364). The inclusion and donor selection criteria are previously described [7] .
Supportive Care
We followed standard guidelines for supportive care established at the National Institutes of Health Clinical Research Center (NIH CC) for patients undergoing allogeneic HCT.
Flow Cytometry
CD14
+ monocytes, CD3 + /CD56 + NK cells, CD19 + B lymphocytes, and CD3 + T lymphocytes were quantified by flow cytometry pre-HSCT and at designated intervals post-HSCT.
EBV
EBV quantitation was performed on EDTA whole blood. The test was developed and performance characteristics determined by the Department of Laboratory Medicine, NIH and has not been cleared or approved by the USFDA. Reported units of copies/mL were calibrated to International Units (IU)/mL beginning October 2014.
Analysis of Chimerism
Engraftment of donor cells was assessed using polymorphisms in regions known to contain short tandem repeats. Peripheral blood CD14 + , CD3 + /CD56 + , CD19 + , and CD3 + cells were selected using flow cytometry at the designated time points, and chimerism was assessed on these subpopulations. In addition, CD14 + /CD15 + myeloid cells and CD3 + T lymphocytes were selected using immunobeads, and chimerism was assessed on the selected cells. The lower limit of sensitivity for this method is 1-3% of donor-type polymorphic markers in the mixture; these sensitivities are on the basis of studies using mixtures of known proportions of allogeneic DNA samples.
Pathology
Pathology examination of hepatic tumors was performed with stains for smooth muscle actin, CD31, CD34, c-KIT, desmin, and HHV-8. In situ hybridization for EBV was performed with EBER probe. Immunoperoxidase and in situ hybridization were developed and their performance characteristics determined by the Laboratory of Pathology, NCI and are not FDA cleared or approved.
Molecular Pathology
Molecular pathology examination of bone marrow aspirates consisted of DNA extraction (PSS USA Magnatron System BLX automated DNA extraction robot) and PCR amplification for detection of immunoglobulin (IGH and IGk) and T cell receptor gene (TRG locus) rearrangements [8] . Products were analyzed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer and electropherograms analyzed using GeneMapper software version 4.0. Additional reactions were performed on the IGk locus using the Biomed II primer set [9] , same analysis. IGH PCR is capable of detecting a clonal population comprising 2-10% of the B cell population. For the TRG locus, PCR was performed as described [10] . These tests were developed and their performance characteristics determined by the Molecular Diagnostics Unit of the Laboratory of Pathology, NCI and have not been cleared or approved by the USFDA.
Results
Case Description
The patient is a 24-year-old man, whose course antecedent to the development of an EBV-associated spindle cell tumor of the liver has been described [11] . In brief, 6 years prior to transplantation, he had immigrated to the USA from the Philippines, and in the same year had developed Mycobacterium szulgai lymphadenitis and pulmonary disease. He was successfully treated with combined surgical and medical therapy. He had recurrent otitis and pneumonias during childhood and persistent warts of the hands and feet. Six months prior to evaluation at the NIH CC, he had new pulmonary and skin disease due to MAC. Initial hematologic evaluation revealed multilineage cytopenias (T, B, and NK lymphocytes; monocytes; and eventually neutrophils) and a hypocellular marrow. With a clinical phenotype consistent with the MonoMAC syndrome, mutation analysis of GATA2 demonstrated a single base transition, cDNA 1186 C > T causing a substitution of tryptophan codon for arginine at amino acid 396 (R396W). This mutation has been reported previously in GATA2-deficient patients [12] .
Computed tomography of the chest and abdomen, performed to assess the extent of remnant mycobacterial disease, revealed multiple enhancing lesions in the liver initially felt to be consistent with abscesses. An EBV serum PCR was positive at log 3.53. Needle biopsy of two liver lesions showed a well-circumscribed spindle cell neoplasm with a very low mitotic rate and no areas of necrosis. The hepatic parenchyma adjacent to the tumor showed mild inflammation but was otherwise normal. The tumor cells reacted with antibodies against smooth muscle actin and were negative for HHV-8, CD34, and CD31. In situ hybridization for EBV using the EBER probe was positive in all tumor cells but negative in the adjacent normal liver, consistent with an EBV-associated smooth muscle tumor (SMT).
He returned 6 months later with intermittent back pain in the lower cervical and thoracic spine. This symptom had been evaluated 5 months previously, and no radiographic findings were present. Computed tomography of the chest, abdomen, and pelvis revealed stable hepatic lesions. However, MRI demonstrated multiple enhancing liver lesions, the largest of which was ∼3 cm in transaxial diameter and multiple enhancing lumbar and thoracic vertebral lesions. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) of the torso demonstrated mediastinal and left hilar adenopathy, a splenic lesion, and 7-8 hepatic areas of hypermetabolism, the largest in the R tip inferiorly. There were scattered hypermetabolic skeletal lesions in thoracic vertebrae, the left scapula, and right pelvis (Fig. 1) .
Immediately prior to transplant, his exam was significant for normal vital signs and a persistent wart on the right hand.
He had mild tenderness of the spine with palpation. Laboratory evaluation was notable for pancytopenia (WBC 2.39 K/μl, Hgb 11.6 g/dl, platelets 71 K/μl, ANC 1100 K/ μl, ALC 280 K/μl, AMC 0). There was hypoalbuminemia 3.3 g/dl (3.7-4.7) and elevation of alkaline phosphatase 197 U/L (37-116) and alanine aminotransferase 60 U/L (6-41). Whole blood PCR for EBV was 3.10 log10, and CMV, HHV6, and adenovirus PCRs were negative.
The peripheral blood smear showed mild polychromasia with macrocytosis, anisopoikilocytosis, with dacrocytes and fragmented red cells. There was moderate leukopenia, marked lymphocytopenia, and mild eosinophilia and thrombocytopenia. Bone marrow biopsy revealed a hypocellular marrow (30%) with no evidence of dysplasia or increased blasts, and GATA2-deficiency characteristic abundant megakaryocytes with hypolobation and abnormal separation of nuclear lobes, decreased peripheral blood monocytes and bone marrow CD20 + cells. The patient underwent 10/10 HLA-matched sibling peripheral blood stem cell transplant. Conditioning for the HSCT consisted of fludarabine 40 mg/m 2 IV once daily for 4 days (−6 through −3) and busulfan 3.2 mg/kg IV once daily for 4 days (−6 through −3). Adjustments to busulfan doses are based on a test dose administered 5-14 days prior to conditioning. On day 0, the patient received 5 × 10 6 CD34 + cell/kg of the recipient's body weight of granulocyte-colony stimulating factor (GCSF) mobilized PBSCs from his EBV-CA IgG + sister. Engraftment occurred on day 10 with whole blood chimerism 96% (CD3 66% and myeloid 100%) at 2 weeks and bone marrow 90% donor. The transplant was complicated by cutaneous graft-versus-host disease (GVHD) that was responsive to topical steroids. Post-transplant GVHD prophylaxis consisted of methotrexate 5 mg/m 2 IV on days +1, 3, 6, and 11 and tacrolimus daily from day −3 until day +180.
Immunophenotypes and EBV viremia through the posttransplant course are seen in Table 1 . Reconstitution of NK cells preceded that of CD19 + cells. EBV viremia was assessed twice weekly through day 60 and weekly thereafter, and was suppressed immediately after transplant and only transiently reappeared at very low levels thereafter, with the 3-year follow-up viral load again undetectable. The patient's pain (primarily spinal) remitted soon after transplantation and he has remained asymptomatic since. Radiology, including MR of the liver and PET-CT scans of the torso, has demonstrated stability or involution of solid lesions and loss of PET enhancement in the liver, spleen, and spinal lesions (Fig. 1) .
Discussion
GATA2 deficiency predisposes to multiple infectious and malignant sequelae, including those related to EBV infection. Solid tumors of mesenchymal cell origin are associated with EBV, as described in the original MonoMAC report [13] [14] [15] . Other immunodeficient states, including HIV infection, immunosuppression after solid organ transplant, and congenital immunodeficiencies, are also predisposing factors to these tumors [16] [17] [18] [19] [20] . We have used HSCT successfully in GATA 2-deficient patients to correct immunodeficiencies leading to mycobacterial and viral infections, and to correct myelodysplastic syndromes and high-risk cytogenetic abnormalities. However, this is the first report of reversal of an EBV-associated smooth muscle tumor with HSCT in a patient with GATA2 deficiency.
Current therapies for EBV-related disease most often include decreasing iatrogenic immunosuppression and using monoclonal antibodies that target the major hematopoietic reservoir of EBV, CD20 + B lymphocytes [21] . Since evidence supports the independent infection of smooth muscle cells, we did not believe that this approach would be sufficient, despite its use in conjunction with surgical resection and a reduction in immunosuppression in one report [22, 23] . Anti-viral therapies have not been shown to have a role in the treatment of any condition associated with EBV, perhaps because the oncogenic role a b f c d e Fig. 1 a MRI of EBV is not dependent on independent viral replication. EBV-targeted cellular therapies have gained acceptance for the treatment of post-transplant lymphoproliferative disease, but the expression of EBV antigens in smooth muscle tumors differs from that seen in lymphoproliferative EBV tumors, suggesting that this approach might not be successful in this patient [24] . Radiation therapy, doxorubicin in combination with olaratumab, and many other chemotherapeutic regimens have been used to treat softtissue sarcomas with variable success [25] . Substitution of sirolimus for other immunosuppressants may have contributed to regression of a hepatic tumor in a kidneytransplant recipient [26] . We have previously reported on outcomes associated with HSCT for GATA2 deficiency [7] . The current case represents successful transplantation and repair of immune defects as evidenced by normalization of cell counts, marrow findings, and absence of recurrence of sentinel infections or new infections consistent with the immunodeficiency. We used radiology, nuclear medicine, chemistry, and virologic studies to establish and follow the disease in our patient. MR of the abdomen demonstrated stable or regressing lesions at 3 years, and serial PET-CTs post-transplantation revealed normalization of previously involved sites, including bone, spleen, and liver lesions. We do not have pathologic confirmation to establish the etiology of all of the PET-avid lesions in the spine prior to transplant. However, the frequent multifocal disease and association with vascular smooth muscle cells in previous reports of EBV-related smooth muscle tumors is consistent with the PET finding. Alternatively, our patient had had multifocal disease with two mycobacterial infections, but these never required clinical consideration in the immediate pretransplant or transplant course [27] .
We did not systematically assess immunity to EBV pretransplant, relying instead on a global assessment of immunodeficiency as represented by cytopenias, and are thus unable to compare the restoration of immunity in a virus-specific fashion. Because of the nature and anatomy of the smooth muscle tumor, we are dependent on comparisons of size and PET avidity to presume regression and cure. Nevertheless, we have demonstrated that HSCT to reverse the immunodeficiency associated with GATA2 deficiency provides a durable control of an EBV-related smooth muscle malignancy after 3 years of follow-up.
